secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2022-07-15T23:59:59+00:00
Accession:  0001493152-22-019381
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic presents Phase 1/2 OT-101 pancreatic cancer data; median OS doubled in patients receiving subsequent chemo
--------------------------------------------------------------------------------

- 55% of OT-101-treated pancreatic cancer patients had long-term disease control (21 of 37 pts).
- Median OS doubled to 9.3 vs 2.6 months (p<0.0001) for those who received subsequent chemotherapy.
- High AUC associated with improved OS: 9.6 vs 2.4 months (p=0.0006).
- OT-101 PK dose proportional (p<0.0001).
- Presentation from JCA-AACR conference available on company website and YouTube.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315222019381/0001493152-22-019381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315222019381/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-019381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer